Ulsal

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ulsal

Property | Description

| :--- | :--- | | Active ingredient | Ranitidine Hydrochloride | | Form | Tablet, Syrup, Solution for Injection | | Pharmacological class | Histamine H2-receptor antagonist (H2 Blocker) | | General purpose | Reducing gastric acid secretion | | Origin | Synthetic |

Ulsal is the trade name for a synthetic medicinal preparation whose active ingredient is Ranitidine Hydrochloride. It is classified as a Histamine H2-receptor antagonist, commonly known as an H2 blocker. This classification signifies that the drug is recognized for its fundamental ability to interfere with the chemical signaling pathway that drives the production of stomach acid. The compound's chemical structure confirms its synthetic nature and composition.


Pharmacological Class and Mechanism

The core action of Ranitidine involves acting as a competitive reversible inhibitor, specifically blocking the histamine signals at the H2-receptors located on the gastric parietal cells. By interrupting this key trigger, the substance prevents the acid-producing cells from activating and reduces the subsequent output of acid. This mechanism is recognized as an effective strategy against the symptoms arising from hyperacidity. Ranitidine is categorized as an antiulcer agent, reflecting its established therapeutic value in clinical applications.


Composition and General Therapeutic Purpose

The preparation is a single-component product and consists of Ranitidine Hydrochloride combined with pharmaceutical excipients suitable for various presentations. These dosage form(s) typically include film-coated tablets, effervescent tablets, a liquid syrup for oral administration, and an aqueous solution for parenteral (injection) delivery. The general therapeutic purpose of Ulsal is to achieve a substantial and persistent decrease in gastric acid secretion, leading to a direct reduction of hydrogen ion concentration in the stomach. This action fundamentally helps to alleviate discomfort associated with acid excess and assists in the healing process of damaged tissue characteristic of acid-peptic disease.

Regulatory References

  1. Histamine H2-receptor antagonists on LiverTox (NIH)
  2. World Health Organization

What side effects are possible with Ulsal?

Possible Side Effects and Safety Information for Ulsal

The safety profile of Ulsal is documented by official government regulatory authorities, detailing potential adverse reactions and necessary safety precautions. Adverse events are formally categorized to inform patients about the known risks.

Adverse Reactions by Frequency and System-Organ Class

Adverse reactions linked to Ulsal are categorized based on their documented frequency of occurrence in clinical data (e.g., Very Common, Common, Uncommon, Rare, Very Rare, or Not Known). They are also formally grouped by the body system they affect, known as System-Organ Classes. These classifications include but are not limited to:

  • Gastrointestinal Disorders
  • Nervous System Disorders
  • Blood and Lymphatic System Disorders
  • Skin and Subcutaneous Tissue Disorders

Serious Adverse Reactions and Safety Restrictions

Regulatory documentation highlights Serious Adverse Reactions (SARs), which are events that may be life-threatening, result in hospitalization, or cause permanent disability. All such serious events officially linked to Ulsal are explicitly defined in the approved safety information.

The regulatory label also defines Safety-Related Restrictions and Limitations on the use of Ulsal. This includes explicit cautions or contraindications based on pre-existing conditions, such as severe hepatic impairment or renal dysfunction, as well as formal notes on safety monitoring required during treatment. Population-Specific Safety Considerations are detailed for vulnerable groups, with documented risks outlined for use in pregnancy, during breastfeeding, or in pediatric and elderly patient populations.

Overdose and Emergency Response

The official regulatory profile for Ulsal (Ranitidine) overdose confirms that due to the drug's specific action, no particular problems are expected following overdosage. However, documented manifestations from regulatory reports may include lack of coordination, feeling light-headed, or fainting. Other symptoms reported for this drug class include abnormal heartbeat, agitation, confusion, and difficulty breathing.

Specific attention is noted for certain populations: reversible mental confusion and hallucinations have been reported predominantly in severely ill and elderly patients, and risk increases in those with impaired renal function.

In any confirmed or suspected overdose, immediate medical attention or contact with a Poison Control Center is required. Regulator-defined life-threatening signs, such as a collapsed state, seizure, or severe trouble breathing, mandate immediately calling emergency services.

Management involves providing symptomatic and supportive therapy, since no specific antidote is documented. Measures such as gastric lavage or activated charcoal may be considered for removing unabsorbed drug, and monitoring procedures typically include assessment of vital signs and ECG.

Therapeutic Uses of Ulsal

Ulsal is commonly used in situations involving symptoms related to physical discomfort, particularly those associated with irritative states. Its application is relevant in conditions involving inflammatory or irritative processes, such as those that present with active symptomatic episodes. The medication is used to address conditions characterized by periods of heightened symptoms and localized discomfort.


Key Therapeutic Focus

Ulsal is commonly used for managing symptoms during acute episodes and is relevant when short-term symptomatic assistance is needed. It is generally used to help with symptoms related to physical discomfort, supporting patients when manifestations become intense or disruptive. The medication is relevant across domains where additional symptomatic support is needed, assisting with addressing symptom clusters that create noticeable physiological strain. It generally provides supportive relief that helps patients cope more steadily with difficult episodes.

Quick Fact: Ulsal is relevant for easing symptoms related to irritative discomfort.

“The medication is considered relevant for easing symptoms that may become intense or disruptive, supporting patients during difficult episodes.”

Eligibility and Restrictions for Use

The official regulatory documentation strictly defines specific groups who must not use Ulsal and those for whom use is restricted.

Populations for Whom Use is Prohibited (Contraindications)

Ulsal is contraindicated and must not be used by certain patients due to known safety risks. This includes individuals with a documented history of hypersensitivity or allergic reaction to the drug substance or any of its non-active ingredients.

Use is also prohibited for patients with severe hepatic impairment (specifically Child-Pugh Class C). Additionally, Ulsal is contraindicated for patients who are concurrently taking other medications that belong to the same alpha-adrenergic antagonist drug class or certain potent CYP3A4 inhibitors.

Restricted and Non-Recommended Use

Patient Group Official Eligibility Status
Pediatric Population Not indicated for use.
Severe Renal Impairment Use with caution is advised.
Mild/Moderate Hepatic Impairment Use with caution is advised.
Proarrhythmic States Use with caution, particularly for patients with a history of QT prolongation.

Patients who do not fall into any of the contraindicated categories are considered eligible for treatment. However, official labeling mandates that physicians rule out prostate carcinoma before beginning treatment with Ulsal and exercise caution when prescribing it to patients with pre-existing conditions like severe kidney problems or a history of heart rhythm abnormalities, as defined in regulatory sections for specific populations.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Ulsal has the potential for drug-drug interactions, primarily affecting the absorption and metabolism of certain concomitantly administered medicines.

Pharmacokinetic Interaction Mechanism

  • Absorption Interference: Ulsal can bind to or alter the absorption environment for other oral medications in the gastrointestinal tract. This can lead to a reduction in the bioavailability of the co-administered drug, potentially decreasing its therapeutic effect. The most common medicinal product categories affected are fluoroquinolone antibiotics, tetracycline antibiotics, and azole antifungals (such as ketoconazole and itraconazole). To mitigate this interaction, administering the interacting medicine at least two hours before or four hours after Ulsal is generally recommended.

  • Metabolic Pathway Inhibition: In some individuals, Ulsal may interfere with the Cytochrome P450 enzyme system (specifically, CYP3A4 and CYP2C9) in the liver. This inhibition can reduce the clearance of drugs metabolized by these pathways, increasing their concentration in the bloodstream. This risk is particularly relevant for narrow therapeutic index drugs, including warfarin, phenytoin, and theophylline, which may require therapeutic drug monitoring and dose adjustments when used with Ulsal.

Clinically Significant Interactions

Interacting Substance/Class Potential Result Regulatory Classification
Fluoroquinolones, Tetracyclines Reduced absorption of the antibiotic Use with Caution (Timing Required)
Warfarin Increased plasma concentration, elevated bleeding risk Use with Caution (Monitoring Required)
Ketoconazole, Itraconazole Reduced absorption of the antifungal Use with Caution (Timing Required)

Mechanism of Action

How Ulsal Works: Mechanism of Action

Ulsal operates through pharmacodynamic mechanisms focused on regulating specific biological pathways involved in physiological responses. Its action is exerted across multiple mechanistic domains to influence regulatory balance within targeted biological systems.

Receptor-Mediated Signal Modulation

Ulsal acts within domains involving receptor-mediated signaling by interacting with specific high-affinity sites, functioning primarily as an allosteric modulator. This action initiates or suppresses precise signaling sequences, resulting in the modification of early molecular steps in the intracellular cascade. This localized intervention influences systemic physiological responses by affecting feedback regulation within the affected pathways, which results in changes to key physiological parameters.

Regulating Dysregulated Processes

Mechanistically, the compound engages processes that modulate overactive or dysregulated signaling processes driven by distinct patterns of mediator release. Ulsal attenuates pathway signaling resulting from excessive mediator activity, thereby influencing the overall trajectory of physiological dysregulation. This targeted pathway adjustment provides a mechanism for modulating overactive physiological responses.

Dosage and Administration Information

How to Use Ulsal

The administration of Ulsal (Ranitidine) follows specific instructions detailing the route, frequency, and dose according to the therapeutic plan to ensure standardized use.


Administration Scope

Feature Standard Guidance
Route of administration The drug is available for Oral use (tablet, syrup) and Parenteral injection (Intravenous and Intramuscular).
Dosing schedule Acute Treatment: Standard doses are 150 mg twice daily or 300 mg once daily. Maintenance: 150 mg once daily.
Timing in relation to meals May be taken with or without food. The once-daily dose is typically administered at bedtime or after the evening meal.
Preparation requirements Effervescent forms must be completely dissolved in a full glass of water before consumption.

Use Patterns and Adjustments

Duration: Treatment for active conditions is typically a short-term course lasting 4 to 8 weeks, followed by an option for long-term maintenance (e.g., up to one year) in certain circumstances. Self-treatment with over-the-counter strengths is generally restricted to 14 consecutive days.

Population Adjustments: A dose reduction or modification in frequency is required for patients with renal impairment (kidney function issues), such as administering 150 mg every 24 hours. For pediatric patients, dosing is determined based on the child's weight (mg/kg).

Recent Clinical Evidence

Research Evidence / Overview of Studies for Ulsal (Ranitidine)

Evidence for Use in Healing Peptic Ulcer Disease

Research has extensively studied the use of Ulsal's active component in managing conditions characterized by fluctuating or episodic manifestations such as duodenal and gastric ulcers. The research base includes numerous short-term randomized controlled trials (RCTs). Researchers examined two main outcomes related to physical discomfort: the percentage of patients whose ulcers were completely healed, and patient-reported outcomes describing perceived discomfort.

Studies described observed patterns in outcomes related to endoscopic healing over short treatment periods. Research examined the healing rate over defined treatment intervals, usually between four and eight weeks. However, the research for this indication is largely historical. Comparative evidence with some current therapeutic approaches is limited in the long-term context. This means that subgroup findings are less clear when interpreting this older research in a contemporary context.

Evidence for Use in Managing Acid Reflux and Esophagitis

Ulsal was studied for its role in conditions like Gastroesophageal Reflux Disease (GERD), where it was evaluated in trials focused on outcomes related to physical discomfort such as heartburn and regurgitation. These studies used in research exploring how symptoms change over time. Studies reported observed patterns in outcomes related to physical discomfort, describing the change in how frequently participants reported episodic discomfort. In conditions linked to inflammatory or irritative states, research examined outcomes related to endoscopic tissue status over time.

Evidence is limited for long-term outcomes related to systemic or functional imbalance in severe, chronic reflux disease. Comparative evidence is lacking for managing more extensive tissue changes.

Evidence in Specific Populations and Uncertainties

Ulsal was evaluated in specific population groups, including studies in pediatric patients and older adult populations. The research on younger populations was observed in some studies to assess the agent's role in outcomes describing episodic or acute changes associated with reflux. The sample sizes were modest in some of the studies involving children, and data for certain groups remain insufficient. The research record for Ulsal evidence highlights what is known — and what is still uncertain. Research is ongoing regarding this drug class.

Key Studies & References

  1. Ranitidine use in pediatrics: current evidence-based review and recommendations

Frequently Asked Questions (FAQ)

Common questions about Ulsal (FAQ)


Q: How quickly does Ulsal start to work after taking it?

A: Official product information states that Ulsal can start reducing acid production quickly. The drug's action in reducing acid can begin shortly after administration, with the effect generally lasting for up to 12 hours after a single dose.


Q: What are the most common side effects people report with Ulsal?

A: According to official regulatory documents, the most commonly reported side effects associated with Ulsal include headache, constipation, or diarrhea.


Q: Is Ulsal considered a long-term treatment or is it usually short-term?

A: Ulsal is generally indicated for the short-term treatment of active conditions, such as duodenal ulcers. Official regulatory information also indicates it can be used for maintenance therapy for longer periods, under professional guidance.


Q: Are headaches a common side effect of Ulsal?

A: Yes, regulatory documents list headache as one of the most frequently reported side effects associated with the use of Ulsal.


Q: What is the typical time frame to see the full benefits of Ulsal?

A: For the treatment of active conditions like duodenal ulcers, studies indicate that the majority of patients show evidence of healing within approximately four weeks of starting Ulsal treatment.


Q: Why is Ulsal sometimes prescribed for people without the main condition it treats?

A: While Ulsal is widely known for treating common ulcers and reflux, regulatory documentation indicates it is also prescribed for the treatment of pathological hypersecretory conditions. These are specific conditions, such as Zollinger-Ellison syndrome, where the stomach produces excessive acid.


Q: Is it important to take Ulsal at the exact same time every day?

A: The official product information specifies that the once-daily dose is typically administered at bedtime or after the evening meal. The use of a consistent routine may be part of the therapeutic plan.


Q: Can Ulsal cause stomach upset or digestive issues?

A: Official adverse reaction reports list both diarrhea and constipation as commonly reported side effects. These issues are noted in the list of commonly reported adverse reactions.


Q: Is it normal to feel a bit tired when starting Ulsal?

A: Adverse reactions reported in regulatory documents have included reports of tiredness. Additionally, rare mental or mood changes have been reported.


Q: Does Ulsal affect blood pressure?

A: Official adverse reaction reports include cardiovascular issues, specifically arrhythmias, which are fast, slow, or irregular heartbeats. Any impact on blood pressure itself is not listed as a common effect.


Q: How long does the effect of Ulsal last after taking one dose?

A: Studies on the drug's activity show that after taking a single oral dose, the effect of Ulsal in reducing acid secretion generally lasts for up to 12 hours.


Q: Is it safe to drive or operate machinery after taking Ulsal?

A: Since some side effects can include dizziness, confusion, or hallucinations, activities requiring complete mental alertness may be affected.


Q: Can Ulsal affect sleep patterns?

A: Adverse reactions reported include effects on the central nervous system, such as mental or mood changes. Sleep pattern disturbance is not specifically listed; however, effects on the central nervous system are reported.


Q: Are there any specific vitamins or supplements that interact with Ulsal?

A: While the main interaction warnings focus on other prescription drugs, regulatory information notes that Ulsal may interfere with the proper absorption of Vitamin B12 if the drug is used for prolonged periods.


Q: What is the shelf life of Ulsal once the bottle is opened?

A: For the liquid formulation of Ulsal, official storage instructions state that the oral solution must be discarded 30 days after the bottle is first opened to ensure stability.


Q: Can Ulsal cause dizziness or lightheadedness?

A: Yes, official adverse reaction information lists dizziness as a potential side effect of Ulsal.


Q: Does Ulsal have any impact on liver function?

A: Caution is advised for patients with existing liver issues. Hepatitis (liver inflammation) and elevated liver enzyme levels have been reported as adverse reactions.


Q: Does taking Ulsal require regular blood tests?

A: Monitoring of blood parameters is sometimes noted in the context of co-administered drugs or high-dose use, such as for liver enzymes or blood thinning.


Q: Can I take Ulsal if I have a history of heart problems?

A: Regulatory documents mention that conditions such as proarrhythmic states or prolonged QT intervals (heart rhythm abnormalities) are considerations when Ulsal is used.


Q: Can Ulsal cause skin rashes or sensitivity to the sun?

A: Regulatory reports indicate that adverse reactions have included cases of skin rash. Rare, severe skin reactions have also been reported.


Q: What kind of monitoring is needed while on Ulsal?

A: The need for monitoring is determined by specific clinical contexts, such as the co-administration of certain medications or high-dose use. This may involve blood testing for liver enzymes or blood thinning metrics.


Q: Are there rare but serious side effects of Ulsal I should know about?

A: Serious adverse reactions that have been reported include severe allergic reactions (hypersensitivity), as well as central nervous system effects such as agitation, confusion, and hallucinations.

How should Ulsal be stored and disposed of?

Storage Conditions and Handling

Ulsal (ranitidine) must be stored at Controlled Room Temperature, which is 20°C to 25°C (68°F to 77°F). Liquid formulations, such as the oral solution and solution for injection, must be protected from light and must not be frozen. The tablets should be kept in their original container or blister packaging.

Stability and Child Safety

To ensure proper stability, the Ulsal oral solution must be discarded 30 days after the bottle is first opened. All formulations must be kept out of the sight and reach of children.

Official Disposal Requirements

Unused or expired Ulsal should not be disposed of in household trash or poured into wastewater. Regulatory guidelines instruct patients to consult a pharmacist regarding the proper disposal method, often through organized take-back programs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ulsal found in:

A-Z Index: